Anavex Life Sciences (NASDAQ:AVXL) Rating Reiterated by HC Wainwright

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Friday, Marketbeat Ratings reports. They currently have a $40.00 price objective on the biotechnology company’s stock.

Separately, EF Hutton Acquisition Co. I raised shares of Anavex Life Sciences to a “strong-buy” rating in a research report on Monday, July 22nd.

Anavex Life Sciences Stock Up 2.6 %

Shares of AVXL stock opened at $5.65 on Friday. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $10.45. The stock has a market capitalization of $478.23 million, a PE ratio of -11.30 and a beta of 0.61. The firm has a 50 day moving average of $5.68 and a two-hundred day moving average of $4.95.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. During the same quarter in the previous year, the firm posted ($0.14) earnings per share. Analysts expect that Anavex Life Sciences will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Anavex Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of AVXL. Virtu Financial LLC acquired a new stake in Anavex Life Sciences during the 4th quarter worth $202,000. Los Angeles Capital Management LLC raised its stake in Anavex Life Sciences by 51.4% during the 1st quarter. Los Angeles Capital Management LLC now owns 87,931 shares of the biotechnology company’s stock worth $448,000 after acquiring an additional 29,844 shares in the last quarter. Fiduciary Alliance LLC acquired a new stake in Anavex Life Sciences during the 1st quarter worth $67,000. Saxon Interests Inc. acquired a new position in Anavex Life Sciences in the first quarter valued at $136,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Anavex Life Sciences by 30.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 54,850 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 12,728 shares during the period. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.